4188.TWO AmCad BioMed Corporation
- Market cap
- UYU 931M
- P/E
- -
- P/B
- 1.93x
- ROE
- -11.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 4188.TWO undervalued?
Graham numberThe Graham number of AmCad BioMed Corporation cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AmCad BioMed Corporation fundamental analysis
No fundamental analysis for AmCad BioMed Corporation yet.
AmCad BioMed Corporation stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of b…
Full company profileAmCad BioMed Corporation financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AmCad BioMed Corporation annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 63.9M | 85.8M | 61.6M | 65.3M | 53.1M | 30.4M | 26.2M |
| Gross Profit | 42.3M | 60.7M | 38.0M | 41.0M | 32.9M | 10.0M | 11.2M |
| Operating Income | -42.8M | -26.8M | -54.3M | -43.0M | -64.7M | -88.0M | -81.6M |
| EBITDA | -23.2M | -8.56M | -36.7M | -25.6M | -34.4M | -55.5M | -54.7M |
| Net Income | -35.4M | -25.5M | -53.5M | -45.3M | -50.6M | -55.7M | -57.3M |
| EPS | -0.67 | -0.48 | -1.01 | -0.85 | -0.80 | -0.88 | -0.90 |
| Balance Sheet | |||||||
| Total Assets | - | 616M | 554M | 513M | 695M | 623M | 617M |
| Total Liabilities | - | 36.7M | 34.1M | 34.7M | 31.2M | 21.9M | 29.3M |
| Shareholders' Equity | - | 483M | 425M | 381M | 569M | 521M | 516M |
| Cash & Short-term Investments | - | 58.5M | 47.0M | 29.7M | 17.8M | 24.6M | 16.0M |
| Cash Flow | |||||||
| Operating Cash Flow | -50.0M | -39.0M | -34.2M | -41.6M | -51.9M | -47.1M | -56.0M |
| Capital Expenditure | 320K | 2.34M | 614K | 293K | 3.05M | 700K | 0.00 |
| Free Cash Flow | -50.4M | -41.3M | -34.8M | -41.9M | -54.9M | -47.8M | -56.6M |
| Ratios | |||||||
| ROE | - | -5.3% | -12.6% | -11.9% | -8.9% | -10.7% | -11.1% |
| ROA | - | -4.1% | -9.7% | -8.8% | -7.3% | -8.9% | -9.3% |
| Net Profit Margin | -55.4% | -29.8% | -86.8% | -69.4% | -95.2% | -183.1% | -218.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
AmCad BioMed Corporation dividends
AmCad BioMed Corporation has not paid dividends in the last 7 fiscal years.
Who owns AmCad BioMed Corporation
- Insiders 53.18%
- Institutions 0.00%
- Public & others 46.82%
- Shares outstanding 63.3M
- Free float 31.6M
AmCad BioMed Corporation company profile
- Company name
- AmCad BioMed Corporation
- Ticker
- 4188.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No. 167 Fuxing North Road, Taipei, Taiwan, 104
- Phone
- 886 2 2713 6227
- Website
- amcad.com.tw
About AmCad BioMed Corporation
AmCad BioMed Corporation develops computer-aided detection and diagnosis (CAD) software devices primarily in Taiwan. It offers products for early detection and diagnosis of various diseases. The company's products include AmCAD-UT Detection, a CAD device for ultrasound images of thyroid nodules; and AmCAD-UO for detection of obstructive sleep apnea on awake patients. It also developing AmCAD-US, a software device for visualizing and quantifying statistical distributions of backscattered signals echoed by tissue compositions in the body from FDA-cleared ultrasound systems; and AmCAD-UB, an AI Solution for Breast Lesion Detection. The company was incorporated in 2008 and is based in Taipei City, Taiwan.
AmCad BioMed Corporation management
4- Ms. Yi-Li LeeChairman, President & Manager
- Ann ChenFinancial Officer
- Zhao Ming ChenAccounting Supervisor
- Mr. Zhenggang ChenChief R&D Officer